Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

Product description

Amikacin Solution for Injection 
Reference Product: Briklin® / BRISTOL-MYERS SQUIBB
Description: Amikacin sulfate is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella species, Enterobacter species, Serratia species, and Acinetobacter species. 
Dossier Status: EU CTD Available (500mg/2ml) & Q3 2021 (1g/4ml)
Stability Studies: Zone II / Zone IVb
Shelf life: Two (2) years
Batch Size: 18,180 vials (500mg/2ml) & 9,090 vials (1g/4ml)
Pack Size: BT x 1 vial
Read more

Specifications

Categories Generic APIsGeneric Antibiotics; Finished Dosage FormsInjectables; Finished Dosage FormsOut-licensing
Sales markets Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from Greece
Selling Points International Approvals/Standards

More products from ANFARM HELLAS S.A.

View all our products (37)
Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

Contact information

Address

Telephone

Website

View all contact information
Customized drug delivery from technology to therapy

Customized drug delivery from technology to therapy

Your innovation. Our ability to bring it to market.

Your innovation. Our ability to bring it to market.

CONTENT GROUP

CONTENT GROUP

Wavelength Pharmaceuticals

Wavelength Pharmaceuticals

Discover Aptar Pharma, the go-to drug delivery expert

Discover Aptar Pharma, the go-to drug delivery expert